Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study

Amy S. Paller; John Browning; Lawrence Charles Parish; Christopher G. Bunick; Zachary Rome; Neal Bhatia

doi:10.1016/j.jaad.2022.02.060

Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study

Amy S. Paller, John Browning, Lawrence Charles Parish, Christopher G. Bunick, Zachary Rome, Neal Bhatia

Division of Ambulatory Care

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Journal	Journal of the American Academy of Dermatology
DOIs	https://doi.org/10.1016/j.jaad.2022.02.060
State	Accepted/In press - 2022

Keywords

congenital ichthyosis
isotretinoin
retinoids
scaling
topical therapy

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2022.02.060

Cite this

Paller, A. S., Browning, J., Parish, L. C., Bunick, C. G., Rome, Z., & Bhatia, N. (Accepted/In press). Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2022.02.060

Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis : Results from a phase 2a proof-of-concept study. / Paller, Amy S.; Browning, John; Parish, Lawrence Charles; Bunick, Christopher G.; Rome, Zachary; Bhatia, Neal.

In: Journal of the American Academy of Dermatology, 2022.

Research output: Contribution to journal › Article › peer-review

@article{9cceef276ffb4ebc8fd4171e290543c9,

title = "Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study",

keywords = "congenital ichthyosis, isotretinoin, retinoids, scaling, topical therapy",

author = "Paller, {Amy S.} and John Browning and Parish, {Lawrence Charles} and Bunick, {Christopher G.} and Zachary Rome and Neal Bhatia",

note = "Funding Information: Funding sources: Supported by Patagonia Pharmaceuticals and a grant from the US Food and Drug Administration ( 1R01FD006079-01A1 ). Funding Information: Medical writing and editorial assistance were provided by Zehra Gundogan, VMD, of AlphaBioCom, LLC, under the direction of the authors and funded by Timber Pharmaceuticals.",

year = "2022",

doi = "10.1016/j.jaad.2022.02.060",

language = "English (US)",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis

T2 - Results from a phase 2a proof-of-concept study

AU - Paller, Amy S.

AU - Browning, John

AU - Parish, Lawrence Charles

AU - Bunick, Christopher G.

AU - Rome, Zachary

AU - Bhatia, Neal

N1 - Funding Information: Funding sources: Supported by Patagonia Pharmaceuticals and a grant from the US Food and Drug Administration ( 1R01FD006079-01A1 ). Funding Information: Medical writing and editorial assistance were provided by Zehra Gundogan, VMD, of AlphaBioCom, LLC, under the direction of the authors and funded by Timber Pharmaceuticals.

PY - 2022

Y1 - 2022

KW - congenital ichthyosis

KW - isotretinoin

KW - retinoids

KW - scaling

KW - topical therapy

UR - http://www.scopus.com/inward/record.url?scp=85127320828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127320828&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2022.02.060

DO - 10.1016/j.jaad.2022.02.060

M3 - Article

C2 - 35271936

AN - SCOPUS:85127320828

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

ER -

Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this